SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma receives EIR for Hyderabad manufacturing facility

26 Feb 2020 Evaluate

Aurobindo Pharma has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from the US Food and Drug Administration (USFDA) for its Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad. The USFDA had inspected company's Unit VIII from October 21, 2019 and October 28, 2019.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1421.85 -14.05 (-0.98%)
24-Apr-2026 11:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1624.65
Dr. Reddys Lab 1320.00
Cipla 1285.60
Zydus Lifesciences 929.65
Lupin 2275.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×